On March 26, 2026, Dogwood Therapeutics, Inc. (NASDAQ: DWTX) released a shareholder letter detailing significant advancements in its development pipeline aimed at addressing cancer-related pain and neuropathy. The letter, authored by CEO Greg Duncan, highlights the recruitment of 145 patients for the Halneuron Phase 2b Chemotherapy Induced Pain Study, with data expected to be released in the fall. Additionally, the company successfully raised $12.5 million in capital during the quarter, ensuring operational continuity through the anticipated data release. The letter also announced the filing of an investigational new drug application for SP16 IV, a potential treatment for neuropathy and inflammation caused by chemotherapy. This application is backed by a royalty-free global development and commercialization license. Furthermore, Dogwood is advancing a chemically equivalent synthesized version of Halneuron for Phase 3 development, which is expected to reduce manufacturing costs and improve yields. The company is optimistic about the upcoming milestones for 2026, including the commencement of dosing patients in the SP16 Phase 1b study and the full recruitment of the Halneuron Phase 2b study this summer. The letter concludes with a commitment to timely communication of corporate progress to shareholders.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.